Global Pediatric Medicines Market 2017-2021

  • ID: 4368842
  • Report
  • Region: Global
  • 91 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5
Analysts forecast the global pediatric medicines market to grow at a CAGR of 4.97% during the period 2017-2021

FEATURED COMPANIES

  • Abbott
  • Eisai Pharmaceuticals
  • Glenmark
  • Heron Therapeutics
  • Merck Sharp & Dohme
  • RedHill
  • MORE
About Pediatric Medicines

Analysts forecast the global pediatric medicines market to grow at a CAGR of 4.97% during the period 2017-2021

The pediatric drug market plays a pivotal role in the pharmaceutical industry. There are several vendors, who provide healthcare services and products for pediatric population. The pediatric medicines market is one of the important segments in the pharmaceutical industry. Infants are prone to infections owing to their under-developed immune system. The presence of a large pediatric population, especially in APAC combined with the population being more prone to infections and illness will increase the demand for pediatric medicines.

The pediatric medicines market is one of the emerging markets in the pharmaceutical sphere with huge unmet needs and requires support for better innovation and higher R&D investments.

Covered in this report

The report covers the present scenario and the growth prospects of the global pediatric medicines market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
Global Pediatric Medicines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors
  • GSK
  • Novartis
  • Pfizer
  • Sanofi
Other Prominent Vendors
  • Abbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai Pharmaceuticals
  • Eli Lilly
  • F. Hoffman-La Roche
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Ipca Laboratories
  • Lupin Pharmaceuticals
  • Merck Sharp & Dohme
  • RedHill
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
Market Drivers
  • High pediatric population
  • For a full, detailed list, view the full report
Market Challenges
  • Usage of off-label drugs
  • For a full, detailed list, view the full report
Market Trends
  • Inorganic growth strategies
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

Research methodology is based on extensive primary and secondary research:
  • Primary research includes in-depth interviews with industry experts, vendors, resellers and customers
  • Secondary research includes the publisher's platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by government agencies
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Eisai Pharmaceuticals
  • Glenmark
  • Heron Therapeutics
  • Merck Sharp & Dohme
  • RedHill
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market overview
  • Five forces analysis
PART 06: Pipeline analysis
  • Phase I molecules
  • Phase II molecules
  • Phase III molecules
PART 07: Market segmentation by Route of drug administration
  • Enteral RoA
  • Parenteral RoA
  • Topical RoA
PART 08: Market segmentation by disease type
  • Respiratory diseases
  • Infectious diseases
  • Gastrointestinal diseases
  • CNS diseases
  • Oncological diseases
  • CVDs
  • Others
PART 09: Geographical segmentation
  • Pediatric medicines market in Americas
  • Pediatric medicines market in EMEA
  • Pediatric medicines market in APAC
PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
  • Oral soluble films
PART 11: Market trends
  • Inorganic growth strategies
  • Government initiatives
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • GSK
  • Novartis
  • Pfizer
  • Sanofi
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Factors influencing the global pediatric medicines market
Exhibit 02: Key focused therapeutic areas in global pediatric medicines market
Exhibit 03: Major acute pediatric diseases
Exhibit 04: Major chronic pediatric diseases
Exhibit 05: Global pediatric medicines market: Major growth drivers
Exhibit 06: Global pediatric medicines market 2016-2021 ($ billions)
Exhibit 07: Opportunity analysis in global pediatric medicines market
Exhibit 08: Five forces analysis
Exhibit 09: Phase I: Key molecules by vendors
Exhibit 10: Phase I: Key molecules landscape
Exhibit 11: Phase II: Key molecules by vendors
Exhibit 12: Phase II: Key molecules landscape
Exhibit 13: Phase III: Key molecules by vendors
Exhibit 14: Phase III: Key molecules landscape
Exhibit 15: Market segmentation by RoA 2016
Exhibit 16: Characteristics of enteral RoA
Exhibit 17: Global pediatric enteral medicines market 2016-2021 ($ billion)
Exhibit 18: Advantages of liquid dosage form over other enteral routes
Exhibit 19: Global pediatric parenteral medicines market 2016-2021 ($ billion)
Exhibit 20: Various routes of parenteral route administration
Exhibit 21: Various formulations of topical administration
Exhibit 22: Global pediatric topical medicines market 2016-2021 ($ billion)
Exhibit 23: Advantages of topical route of drug administration
Exhibit 24: Global pediatric medicines market segmentation by disease type
Exhibit 25: Various types of respiratory diseases in pediatric population
Exhibit 26: Various types of infectious diseases in pediatric population
Exhibit 27: Various types of gastrointestinal diseases in pediatric population
Exhibit 28: Various types of CNS disorders in Pediatric patients
Exhibit 29: Major oncological disorders seen in pediatric patients
Exhibit 30: Various types of CVDs in pediatric patient
Exhibit 31: Segmentation of global pediatric medicines market by geography 2016 and 2021
Exhibit 32: Global pediatric medicines market by geography 2016-2021 ($ billions)
Exhibit 33: Market scenario in Americas
Exhibit 34: Pediatric medicines market in Americas 2016-2021 ($ billions)
Exhibit 35: Market scenario in EMEA
Exhibit 36: Pediatric medicines market in EMEA 2016-2021 ($ billion)
Exhibit 37: Market Scenario in APAC
Exhibit 38: Pediatric medicines market in APAC 2016-2021 ($ billion)
Exhibit 39: Pediatric population in US 1980-2050
Exhibit 40: Few phase III molecules for pediatric application
Exhibit 41: Few commonly used off-label drugs for pediatric patients
Exhibit 42: Various challenges in pediatric clinical trials
Exhibit 43: Inorganic growth strategies
Exhibit 44: Various government initiatives
Exhibit 45: Competitive structure analysis of global pediatric medicines market 2016
Exhibit 46: Market penetration of various pediatric medicines manufacturers worldwide 2016
Exhibit 47: Strategic success factors of companies in global pediatric medicines market
Exhibit 48: GSK: Key highlights
Exhibit 49: GSK: Strength assessment
Exhibit 50: GSK: Strategy assessment
Exhibit 51: GSK: Opportunity assessment
Exhibit 52: Novartis: Key highlights
Exhibit 53: Novartis: Strength assessment
Exhibit 54: Novartis: Strategy assessment
Exhibit 55: Novartis: Opportunity assessment
Exhibit 56: Pfizer: Key highlights
Exhibit 57: Pfizer: Strength assessment
Exhibit 58: Pfizer: Strategy assessment
Exhibit 59: Pfizer: Opportunity assessment
Exhibit 60: Sanofi: Key highlights
Exhibit 61: Sanofi: Strength assessment
Exhibit 62: Sanofi: Strategy assessment
Exhibit 63: Sanofi: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Eisai Pharmaceuticals
  • Glenmark
  • Heron Therapeutics
  • Merck Sharp & Dohme
  • RedHill
  • MORE
New Research Report - Global Pediatric Medicines Market 2017-2021

The publisher recognizes the following companies as the key players in the global pediatric medicines market: GSK, Novartis, Pfizer, and Sanofi

Other Prominent Vendors in the market are: Abbott, Bristol-Myers Squibb, Cipla, Eisai Pharmaceuticals, Eli Lilly, F. Hoffman-La Roche, Glenmark, Helsinn Healthcare, Heron Therapeutics, Ipca Laboratories, Lupin Pharmaceuticals, Merck Sharp & Dohme, RedHill, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Inorganic growth strategies. Along with the huge unmet need of this market which provide ample organic growth opportunity, the vendors in the market are continuously looking for alliances and acquisitions which provide additional growth booster to the market. Such strategic alliances often result into expanded geographical footprint and impressive product line extension. Such inorganic growth strategies, lead to technological advances due to mutual collaboration in R&D and improved product portfolio, which acts as growth impetus.”

According to the report, one of the major drivers for this market is High pediatric population. The growing pediatric population is one of the key drivers of the global pediatric medicines market. The birth-rate is increasing rapidly in under developed and in developing nations. For instance, according to the Central Intelligence Agency, the highest birth-rate was registered in Niger, which is 4.4%. The birth-rate in densely populated countries such as India and China is also very high. For instance, the birth-rate in India is 1.9% and in China, it is 1.24%.

Further, the report states that one of the major factors hindering the growth of this market is Usage of off-label drugs. The use of off-label drugs for pediatric patients is extensive, both in primary healthcare centers and even in hospitals. It is one of the major issues related to patient safety associated with an increased hazard of adverse drug reactions.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • GSK
  • Novartis
  • Pfizer
  • Sanofi
  • Abbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai Pharmaceuticals
  • Eli Lilly
  • F. Hoffman-La Roche
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Ipca Laboratories
  • Lupin Pharmaceuticals
  • Merck Sharp & Dohme
  • RedHill
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll